|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | C12N 15/13 | (2006.01) |
| C07K 16/24 | (2006.01) | ||
| C07K 16/46 | (2006.01) | ||
| A61K 47/48 | (2006.01) | ||
| C07K 19/00 | (2006.01) | ||
| C12N 15/62 | (2006.01) | ||
| C12N 15/70 | (2006.01) | ||
| C12N 1/21 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 19/02 | (2006.01) | ||
| A61P 37/06 | (2006.01) |
| (11) | Number of the document | 2308975 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10010795.2 |
| Date of filing the European patent application | 2001-06-05 | |
| (97) | Date of publication of the European application | 2011-04-13 |
| (45) | Date of publication and mention of the grant of the patent | 2016-08-10 |
| (46) | Date of publication of the claims translation | 2016-11-10 |
| (30) | Number | Date | Country code |
| 0013810 | 2000-06-06 | GB |
| (72) |
Athwal, Diljeet Singh, GB
Brown, Derek Thomas, GB
Weir, Andrew Neil Charles, GB
Popplewell, Andrew George, GB
Chapman, Andrew Paul, GB
King, David John, GB
|
| (73) |
UCB Pharma, S.A.,
Allée de La Recherche 60, 1070 Brussels,
BE
|
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antikūno molekulės, specifiškos žmogaus naviko nekrozės faktoriui alfa, ir jų panaudojimas |
| Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
| Payment date | Validity (years) | Amount | |
| 2020-05-21 | 347.00 EUR |